Skip to content

Septerna

US · SEPN #2886 by market cap Listed 2024
38.61 -0.59 -1.51%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Septerna

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Founded
2019
CEO
Dr. Jeffrey T. Finer, M.D.,PhD
Employees
130
Headquarters
South San Francisco, California, United States of America
Fiscal year end
12-31
Website
septerna.com

Company profile

Exchange
US
Symbol
SEPN
Market-cap rank
#2886
Listing date
2024-10-25
Market cap
1.84B
Float cap
884.03M
Shares out
47.55M
Float shares
22.90M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Septerna discussion 0 comments

Add a comment